IceCure Medical to Present at 34th Annual Oppenheimer Healthcare MedTech & Services Conference
CAESAREA, Israel, March 7, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that the Company's Chief Executive Officer, Eyal Shamir, will present at the 34th Annual Oppenheimer Healthcare MedTech & Services Conference on Tuesday, March 12, 2024, at 8:00am EST.
- CAESAREA, Israel, March 7, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that the Company's Chief Executive Officer, Eyal Shamir, will present at the 34th Annual Oppenheimer Healthcare MedTech & Services Conference on Tuesday, March 12, 2024, at 8:00am EST.
- Investors may view the presentation at the virtual conference through the following LINK live and for 180 days following conference.
- Mr. Shamir will provide an update on IceCure's latest developments including the Company's ICE3 breast cancer trial with its pending De Novo Classification Request with the U.S. Food and Drug Administration ("FDA") for marketing clearance of ProSense® for the treatment of patients with early-stage, low-risk breast cancer as well as ProSense®'s increasing global commercial reach and the growing body of independent research on the efficacy of cryoablation.